TCGA-55-8616-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.260
- MYOGENESIS+0.240
- ESTROGEN_RESPONSE_EARLY+0.200
- PANCREAS_BETA_CELLS+0.180
- BILE_ACID_METABOLISM+0.140
- ADIPOGENESIS+0.070
- PEROXISOME+0.070
- XENOBIOTIC_METABOLISM+0.070
- ESTROGEN_RESPONSE_LATE+0.050
- HEDGEHOG_SIGNALING+0.050
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.560
- MTORC1_SIGNALING-0.460
- INTERFERON_ALPHA_RESPONSE-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.380
- PI3K_AKT_MTOR_SIGNALING-0.370
- MYC_TARGETS_V2-0.350
- OXIDATIVE_PHOSPHORYLATION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613724 | — | F | 0.916 |
| 2 | C3L-00444 | — | cohortA1 | 0.914 |
| 3 | BS_063ERW0R | pilocytic astrocytoma | — | 0.913 |
| 4 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.911 |
| 5 | BS_V7BJM89K | low-grade glioma | — | 0.904 |
| 6 | C3L-02958 | — | cohortA1 | 0.901 |
| 7 | C3N-02950 | — | cohortA1 | 0.901 |
| 8 | TCGA-55-8512-01A-11R-2403-07 | — | cohortA1 | 0.897 |
| 9 | SJEPD001526_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 10 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |